thought call
perform ok revenu ep upward guidanc
revis qualiti beat concern mani investor sever diabet
product fell short expect ultim put pressur share today
view downward move larg overdon like driven seemingli
over-own posit reflect recent run share ytd vs
understand investor worri overal outlook diabet franchis
importantli trulic think prematur get name
expect rewind contribut signific upsid trulic
vs consensu ra phase initi
come week pois potenti disrupt treatment paradigm
wont know magnitud mace benefit rewind june expect
result ultim clinic meaning yield meaning trulic uptak
given similar trial popul patient seen clinic practicemuch
repres higher-risk patient studi prior cvot overal
noth quarter would point legitim concern go forward
continu like lilli posit head given differenti
revenue/ep growth profil multipl near-term upsid driver see
carri posit sentiment maintain overweight rate pt
near-term catalyst push posit sentiment recogn
strong run point sever event could drive upsid
current level rewind june follow increas class
expans phase tirzepatid trial initi come week data
upward revis long-term guidanc acceler revenu growth/margin
upsid elanco spin long-term safeti tanezumab file
minim expect pain migrain emgal lasmiditan franchis
model chang given perform updat guidanc expect
revenu non-gaap ep
figur page detail
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight exit yz period
new commerci stage portfolio attract diabet
oncolog immunolog asset model
forecast mid single-digit sale low double-digit
ep growth major
pharma averag execut product
cadenc think current multipl
faster expect commerci launch
expect jardianc trulic taltz
baricitinib could drive upsid potenti
re-rat biotech-lik multipl
slow uptak new diabet immunolog
margin pressur early/intermedi pipelin
failur could caus concern long term
million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changepriorcurr chg chg sell million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changecurrentcurr chg chg sell barclay eli lilli co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
